Market Overview

UPDATE: JP Morgan Upgrades The Medicines Company to Overweight on Pipeline Outlook

Related MDCO
The Medicines Company Surges Amid Credit Suisse Upgrade
US Stock Futures Surge Ahead Of Earnings, ADP Data

JP Morgan raised its rating on The Medicines Company (NASDAQ: MDCO) from Neutral to Overweight and increased its price target from $28 to $32.

JP Morgan noted, "This morning the company reported earlier-than-expected positive top-line Phase 3 results from oritavancin's SOLO-1 trial (in acute skin infections), but the crux of our call is on MDCO's overall risk/reward at current levels. Indeed, we believe the company's Angiomax franchise plus the balance sheet is worth nearly $20/sh alone, thus providing a solid value foundation. Then there's upside optionality from the remaining commercial portfolio and pipeline, including Recothrom, Cleviprex, cangrelor, oritavancin and IONSYS. We believe the scarcity of the company's acute-care-hospital–based infrastructure is also a key component to the story."

The Medicines Company closed at $22.29 on Wednesday.

Latest Ratings for MDCO

DateFirmActionFromTo
Dec 2014JP MorganMaintainsOverweight
Nov 2014Credit SuisseUpgradesNeutralOutperform
Oct 2014Credit SuisseMaintainsNeutral

View More Analyst Ratings for MDCO
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (MDCO)

Around the Web, We're Loving...

Get Benzinga's Newsletters